2021
DOI: 10.1136/jitc-2021-002968
|View full text |Cite|
|
Sign up to set email alerts
|

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

Abstract: BackgroundAcute myeloid leukemia (AML) stem cells (LSCs) are capable of surviving current standard chemotherapy and are the likely source of deadly, relapsed disease. While stem cell transplant serves as proof-of-principle that AML LSCs can be eliminated by the immune system, the translation of existing immunotherapies to AML has been met with limited success. Consequently, understanding and exploiting the unique immune-evasive mechanisms of AML LSCs is critical.MethodsAnalysis of stem cell datasets and primar… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
22
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(23 citation statements)
references
References 49 publications
1
22
0
Order By: Relevance
“…In AML, PD-1 expression on effector T cells is modulated at the protein level by interactions between cells. CD200, overexpressed in AML blasts with a suppressive role in the antitumor response [ 104 ], was also recently observed to be linked to PD-1 expression ( 105 ). Coles et al indicated that CD8 T cells from CD200hi AML patients showed higher levels of PD-1, almost twice, compared with CD200lo patients.…”
Section: Introductionmentioning
confidence: 99%
“…In AML, PD-1 expression on effector T cells is modulated at the protein level by interactions between cells. CD200, overexpressed in AML blasts with a suppressive role in the antitumor response [ 104 ], was also recently observed to be linked to PD-1 expression ( 105 ). Coles et al indicated that CD8 T cells from CD200hi AML patients showed higher levels of PD-1, almost twice, compared with CD200lo patients.…”
Section: Introductionmentioning
confidence: 99%
“…In this regard, Levine et al published PhenoGraph, a software for analyzing mass cytometry data that enabled better identification and characterization of LSC (102). Moreover, one recent paper used mass cytometry and RNA-seq to feature CD200 as a LSC-specific immune checkpoint overexpressed in AML LSC (121).…”
Section: Application In the Current Mn Researchmentioning
confidence: 99%
“…Compared to other platforms, MFC is also rather quick, usually providing MRD information within hours, rather than on the order of days, as is required for most molecular-based MRD assessments. MFC can also be used to detect expression of leukemia stem cell (LSC) markers, including CLL1, CD123, CD200, and others [ 30 33 ], and some studies suggest that detection of LSCs within MRD is an adverse prognostic factor [ 31 , 34 , 35 ]. While antibody panels are increasingly standardized, interpretation of MFC requires an experienced pathologist, and inter-laboratory differences in interpretation are not uncommon [ 23 ].…”
Section: Methodologies For Mrd Assessmentmentioning
confidence: 99%